Weight management · Phase 3
SCALE: weight management without diabetes
What was tested?
Liraglutide versus placebo alongside lifestyle intervention in adults with overweight or obesity, excluding diabetes. ↗
Registered primary question: Weight change and the proportions losing at least 5% or more than 10% of baseline weight at week 56; the registry also includes a later diabetes-onset endpoint. ↗
What the reviewed report found
Journal year 2015 · Article summary reviewed 2026-08-19
Reported mean weight loss was 8.4 kilograms with liraglutide and 2.8 kilograms with placebo. At least 5% weight loss was reported for 63.2% and 27.1%, respectively, and gastrointestinal events were common.↗
Keep in context: This paper reports the 56-week comparison. The registered 160-week diabetes-onset endpoint belongs to a longer follow-up question and should not be inferred from this report. ↗↗
Participants, design, limitations and sources
Registry snapshot
- Registry enrollment
- 3,731 · reported actual
- Registry status
- Completed
- Allocation and masking
- Randomized · Double
- Design
- Parallel
- Eligible ages
- 18 Years; maximum not specified
- Registry results
- Posted in this snapshot
Registry source ↗ · Updated 2018-01-19; retrieved 2026-09-20. Registry enrollment is not necessarily the analyzed sample in a publication. Posted registry results and published article results are separate.
SCALE weight-management trial
- Design in the report
- A double-blind, randomized, placebo-controlled trial assessed body-weight change over 56 weeks alongside lifestyle counseling.↗
- Participants in the report
- The trial randomized 3,731 adults without type 2 diabetes who had obesity, or overweight with dyslipidemia or hypertension.↗
- Limitations
- The sponsor-funded trial combined treatment with lifestyle counseling, excluded type 2 diabetes, and used imputation for the reported mean weight-change analysis.↗
This reading covers the article abstract and record metadata. Read its preserved Human Evidence Review →
How the study identity and sources were checked
Study context checked 2026-09-20. Existing article summaries keep their original review dates. This is a selected study reading, not a complete literature or full-text appraisal.
Registry
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes ↗
Protocol identifier: NN8022-1839. Sponsor: Novo Nordisk A/S.
Retrieved 2026-09-20; SHA-256 d6a601e8c8078b3ecb31ca8f2c149e437d19d2de09f56a37cd4165e541e88f9c.
PMID 26132939
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management ↗
Exact trial identity is declared in PubMed’s ClinicalTrials.gov databank field. The registry independently labels this reference RESULT. These source labels do not establish that every result in a paper applies to this trial.
Identity metadata retrieved 2026-09-20. EFetch batch XML; locate MedlineCitation/PMID 26132939. SHA-256 0e6795be99af1c93f3a3e2726fc8a17152661ca29e8dead110bff36feb856127.
Scientific summary uses the original 2026-08-19 source snapshot: SHA-256 5c94f293c86af2a279cfa8ae529f06100cf2dce79b2009b0a6ba26fb9ca9bce6.